Dr. Francine Foss discussed new T-cell NHL therapies, highlighting EBV-related disease classification and CD30+ frontline Brentuximab use. Promising combos include duvelisib with romidepsin or azacytidine. EZH2 and JAK inhibitors showed subtype-specific efficacy. Bispecifics had mixed results; trials continue.